PYC announces that it has obtained data for safe and well-tolerated doses of its co-lead drug candidate (known as VP-001) from a dose range finding study in non-human primates (NHPs) to support continued non-clinical development of this program.
The results represent a key step towards toxicity studies (scheduled for Q1 2022) that will then support initiation of first in human studies for the Company’s Retinitis Pigmentosa type 11 (RP11) program.
Importantly, the results further validate the Company’s drug delivery technology that is utilised throughout PYC’s pipeline. The outcome therefore has positive read-through implications across each of PYC’s five therapies for blinding eye diseases (as well as future ocular programs)
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)